Receipt date: 06/04/2008 10642844 - GAU: 161

Approved for use through 06/30/2008. OMB 0651-003 Dox description: Information Disclosure Statement (IDS) Filed U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMER Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nu

	Application Number		10642844		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Filing Date		2003-08-18		
	First Named Inventor Lewy		y		
	Art Unit		1614	-/-	
	Examiner Name	Royd	s, Leslie A.	/	

| Royds, Leslie A. Attorney Docket Number 90-559-T Remove U.S. PATENTS Pages.Columns.Lines where Examiner Cite Kind Name of Patentee or Applicant Patent Number Issue Date Relevant Passages or Relevant Initial* Nο ode. of cited Document Figures Appear 1 Add If you wish to add additional U.S. Patent citation information please click the Add button. U.S.PATENT APPLICATION PUBLICATIONS Remove Pages.Columns.Lines where Examiner Cite Kind Publication Mame of Patentee or Applicant Publication Number Relevant Passages or Relevant Initial* Nο Code1 Date of cited Document Figures Appear 1 If you wish to add additional U.S. Published Application citation information please click the Add button. Add FOREIGN PATENT DOCUMENTS Remove Pages.Columns.Lines Name of Patentee or Examiner Cite Foreign Document Country Kind Publication where Relevant Applicant of oited Initial* Nο Number3 Code2 i Code4 Date Passages or Relevant Document Figures Appear If you wish to add additional Foreign Patent Document citation information please click the Add button NON-PATENT LITERATURE DOCUMENTS Remo Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s T5 Initials*

publisher, city and/or country where published.

njeceipi dale. 00/04/2000	Application Number	10042044 TUO42044 TUAO. 10			
\	Filing Date	2003-08-18			
INFORMATION DISCLOSU		Lewy			
STATEMENT BY APPLICAL (Not for Submission under 37 CFR 1.		1614			
(NOT 101 Submission under 37 CFR 1.	Examiner Name	Royds, Leslie A.			
	Attorney Docket Num	ber 90-559-T			
1 ARAI et al. "Isoflurane inc Anesthesiology 18(3):228		blood concentrations of metatonin in women," Journal of			
	doles, Tetrahydrocarbazoles and He	in Agonists and Antagonists Derived from exahydro cyclopent[b]innoles," Journal of Medicinal			
3 DEMISCH "Melatonin and 620-22 (1986).	DEMISCH "Melatonin and corusol increase after fluvoxamine [letter]," British Journal of Clinical Pharmacology 22(5): 620-22 (1986).				
4 DESIR et al. "Ritodrine in	ncreases plasma melatonin in wome	en Lancet 1(8317):184-85 (1983).			
5 GARDEET al. "8-methox metabolism," Photochemic	ypsoralen increases dayling plasm stry and Photobiology 60(3) 475-80	a melatonin levels in humans through inhibition of (1994).			
6 GARRATT et al. (1995). * Antagonists Derived from	Mapping the Melatonin Receptor. 2-phenyltryptamines," Journal of M	Neesign and Synthesis of Melatonin Agonists and Medicinal Chemistry 38(7):1132-39.			
7 GROTA et al. "Psoralen ir Sciences 453:385-87(198		Iltraviolet light: "Annals of the New York Academy of			
	e for a phase advance in circadian 98)," Sleep Research 24: 526 (1995	temperature regulation after acute melatonin and a []			
	of both a melatonin agonist and ant louse," International Journal of Obe	agonist on seasonal changes in body mass and energy saity 20(7): 661-67(1996).			
	ment of circadian rhythms by S-200 " Pharmacology Biochemistry and I	098, a metatonin agonist, is dose and plasma Behavior 54:713-18 (1996).			
		p-1H-phenelene derivatives as new conformationally nal Chemistry 39(16): 3089-95 (1996).			

Receipt date: 06/04/2008		Application Number		10642844	10642844 -	GAU:	1614	
		Filing Date		2003-08-18				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for Submission under 37 CFR 1.99)		First Named Inventor	Lewy					
		Art Unit		1614				
		Examiner Name Royds, Leslie A.						
	1	\	Attorney Docket Numb	er	90-559-T		/	
	12	OXENKRUGET al. "Single dose of 1081-85 (1386).	f tranylcypromine increases	human	plasma melatonin	," Biological Psychi	atry 21:	
	13	PALAZIDOU et al. Noradrenaline uptake inhibition increases melatonin secretion, a heasure of noradrenergic neurotransmission, in Vepressed patients," Psychological Medicine 22(2):309-15 (1992).						
	14	REDMAN et al. "Dose dependent effects of S-20098, a metationin agonist on direction of re-entrainment of rat circadian activity rhythms," Psychopharmacology (Berl) 118(4):385-90 (1995).						
	15	SACK "Desmethylimipramine treatment increases melatonin production in humans," Biological Psychiatry 21:406-10 (1986).						
	16	SOUETRE et all. *5-Methoxypsora Dermatology 89(2):152-55 (1987).		elatoni	n levels in humans	," Journal of Investi	igative	
	17	SPASONI et al. "2-Substituted 5-m evaluation of the biological activity	nethoxy-bacyltryptamines: ,," Journal of Medicinal Che	wnthes	sis, binding affinity (36(25):4069-74 (19	for the melatonin re 193).	ceptor, and	
	18	TARZIA at al. "Design and synthes	sis of melatonin receptor ago	onists a	and antagonists," F	armaco 55(3):184-8	87(2000).	
	19	TARZIA et al. "1-(2-Altraneamidoe analogues. Evaluation of the biolo					in	
If you wis	h to a	dd additional pon-patent literatur	e document citation infor	mation	please click the	Add button Ad	d	
			EXAMINER SIGNAT	URE				
Examiner	Signa	iture //Leslie A. Royds/ (03	3/09/2009)		Date Consider	red		
		itial if reference considered, who						

¹ See Kind Coptes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-lettle-code (WIPO Standard St/5). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precode the serial number of the pathot document. ⁴ Kind of occument by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check hark here if English Janguage translation is attached.